Shares of Innoviva Inc. (INVA), a diversified holding company with a portfolio of royalties and other healthcare assets, have lost nearly 14% of their value year-to-date to trade around $11.
The company's royalty portfolio is made up of respiratory assets partnered with Glaxo Group Limited including RELVAR/BREO ELLIPTA and ANORO ELLIPTA.
Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe NowAlready subscribed? Sign in
For comments and feedback: editorial@rttnews.com